Pendulum Therapeutics has teamed up with the Australian Catholic University to investigate the effect of probiotics on metabolism in early menopause.
US biotech company Pendulum Therapeutics has teamed up with bone health care researchers at Australian Catholic University (ACU) to investigate the effect of a targeted formulation of probiotic strains and prebiotic fibers on slowing or halting osteoporosis in early-menopausal women.
Professor Matthias Lorentzon of the Bone and Fracture Health Research Program at the Mary McKillop Institute for Health Research in the ACU will lead the OsteoPreP study.
Microbiome research has expanded rapidly in the past decade leading to the identification of how essential bacterial strains in the gut work to influence health throughout the body. Less common is the relationship between the gut microbiome and bone health. With osteoporosis affecting one in three women over the age of 50 worldwide and the economic cost of related fractures estimated at more than $130 billion by 2050, strategies to improve age-related decline in bone health are essential.
“Research suggests that the gut microbiome, particularly the butyrate-producing bacterial strains, may play an important role in bone health,” Professor Lorentzon said. OsteoPreP was designed based on the knowledge that targeted probiotic strains can increase production of short-chain fatty acids, such as butyrate, affecting not only bone health, but also overall metabolic health, including muscle mass and weight. As we age.When we published this publication, the data shows that formulation of pendulum increased butterfat in a clinical trial, and we were excited to collaborate with their scientists on this project.
“If the study results show what we expect, it is entirely possible that we can avoid osteoporosis in high-risk populations by targeting the microbiome.
While this is primarily a bone health study, researchers are also looking at findings related to memory, muscle mass, fat, blood sugar, mental health, and general well-being. There is an emerging body of evidence linking the gut microbiome to cognitive and muscular function and cardiac metabolism. Such studies suggest that probiotics (healthy gut bacteria) or prebiotics (a food for healthy bacteria, i.e. fiber) can increase the amount of short-chain fatty acids produced by gut bacteria which may contribute to the broader beneficial effects of improving gut health.
Glucose Control in a Pendulum The probiotic combination used in OsteoPreP was previously shown in a randomized, double-blind, placebo-controlled clinical trial to improve A1c and post-meal glucose elevation in people with type 2 diabetes taking metformin.
“If the study results show what we expect, it’s entirely possible that we can avoid osteoporosis in high-risk populations by targeting the microbiome,” said Dr. Orville Colterman, chief medical officer of Pendulum Therapeutics. “Pendulum is leading the way in microbiome research and technology, bringing these new solutions to market. Strong research collaborations, such as the clinical trial with the ACU, will prove that the microbiome is the next frontier in human health.”